Medical
-
Nasus Pharma announced that it has initiated a Phase 2 study of the company’s NS002 epinephrine nasal powder, which the company is developing for the treatment of anaphylaxis. The open-label PK trial is expected to… Read more . . .
-
According to ReCode Therapeutics, the FDA has cleared the 3rd part of an ongoing Phase 2 trial of nebulized RCT2100 CFTR mRNA therapy in cystic fibrosis patients, and enrollment has opened at US sites. The new… Read more . . .
-
MannKind Corporation announced that it has discontinued the Phase 3 ICoN-1 study of MNKD-101 nebulized clofazimine inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease “due to futility” after analysis of data from the… Read more . . .
-
Nasal vaccine developer CastleVax has announced the initiation of a Phase 2 study comparing its CVAX-01 intranasal COVID-19 vaccine to an mRNA-based injectable COVID-19 vaccine. The 6-month study is expected to enroll 200 previously-vaccinated adults… Read more . . .
-
Rein Therapeutics announced that the FDA has lifted a full clinical hold on the Phase 2 “RENEW” trial of the company’s LTI-03 inhaled dry powder caveolin-1-based peptide in patients with idiopathic pulmonary fibrosis (IPF). The… Read more . . .
-
Tonix Pharmaceuticals announced that Massachusetts General Hospital has initiated a Phase 1 trial called FOCUS to evaluate Tonix’s TNX-1900 and TNX-2900 oxytocin nasal sprays in patients with arginine-vasopressin deficiency (central diabetes insipidus). The FOCUS study… Read more . . .
-
GSK has announced that a Phase 3 trial comparing an HFA-152a formulation of Ventolin salbutamol (albuterol) MDI to the currently marketed HFA-134a formulation demonstrated therapeutic equivalence. The company also said that safety of the LGWP propellant… Read more . . .
-
US-based biotech Eradivir announced that a Phase 1/2a trial of its EV25 intranasal antiviral for the treatment of influenza demonstrated that a single 300 mg dose resulted in a significant reduction in lower respiratory tract… Read more . . .
-
Orexo announced that the US Biomedical Advanced Research and Development Authority (BARDA) has awarded the company $8 million to support the development of OX390, a new chemical entity formulated for nasal delivery for the reversal… Read more . . .
-
Tonix Pharmaceuticals has announced plans for a Phase 2 trial of its TNX-2900 intranasal magnesium-potentiated oxytocin in patients with Prader-Willi syndrome (PWS). According to Tonix, the FDA has already cleared the company’s IND for a… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
May 30-June 2: ISAM Congress 2027, Dublin, Ireland
June 23: SMI London, London, UK


